Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
1.053 Leser
Artikel bewerten:
(2)

Royal Philips: Champalimaud Foundation partners with Philips to reduce its diagnostic imaging carbon footprint by 50% in five years

March 15, 2023

Lisbon, Portugal and Amsterdam, the Netherlands -Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, and leading Portuguese translational biomedical research and clinical care provider Champalimaud Foundation, today announced they have signed a strategic partnership aimed at halving the carbon footprint resulting from Champalimaud's use of diagnostic and interventional imaging equipment by 2028.

The transformation of Champalimaud Foundation's imaging technology infrastructure will be enabled by a set of practical, scalable measures and innovations, including equipment upgrades, lifetime extensions, process digitalization, circular financing solutions with takeback, and renewable electricity sourcing. It will help drive the quality and efficiency of care delivery, while also realizing more sustainable healthcare. As a result, many more patients are expected to be able to benefit from the hospital's diagnostic healthcare services.

Global healthcare systems account for 4.4% of global CO2 emissions [1] - more than aviation or the shipping industry [2]. The cooperation between Champalimaud Foundation and Philips is based on a shared commitment to help mitigate climate change - building on Philips' acknowledged expertiseas a health technology company that is driving systemic change towards more sustainable and equitable patient care through the application of EcoDesign, renewable energy sourcing, and workflow improvement through digitalization.

After conducting a baseline assessment of Champalimaud Foundation's current CO2 emissions, Philips will work with the organization to update and renew its diagnostic imaging technology capabilities, keeping it up-to-date with Philips' latest innovations in diagnostic imaging such as CT and MR systems, while also reducing resource demand, increasing the use of recycled materials, and extending equipment lifespans. As a result, Champalimaud Foundation's patients and staff will be able to enjoy the outcome benefits of advanced diagnostic imaging coupled with improved patient and staff experiences and more sustainable healthcare delivery.

"The healthcare sector is a significant contributor to CO2 emissions and therefore has an important role to play in mitigating climate change," said Leonor Beleza, President of the Champalimaud Foundation. "This partnership will allow us to continue to ensure the best care for our patients while at the same time helping to reduce the healthcare sector's environmental impact."

"Alongside improving patient outcomes and increasing efficiency, healthcare providers are increasingly focusing on mitigating their impact on the climate and making more sustainable choices," said Peter Vullinghs, Market Leader Western Europe for Philips. "We have a strong track record in embedding sustainability in our solutions, our operations, and across our supply chain. Leveraging that deep expertise, we are partnering with the Champalimaud Foundation to make a step-change in their environmental impact, while enabling them to pursue their goal of advancing the prevention, early diagnosis and treatment of cancer."

Philips will support Champalimaud Foundation's sustainability targets through a range of health technologies and innovations designed to reduce the foundation's dependency on natural resources and energy consumption. This includes the installation of Philips Spectral CT 7500which uses 62.5% less energy [3]. The installation of Philips' MR helium-free operations' system, Philips MR - Ingenia Ambition 1.5Tthat uses a breakthrough design where the magnetic components are completely sealed and only need seven liters of helium over its lifetime compared to roughly 1,500 liters with other Philips's systems. Additionally, with Philips MR SmartSpeed, the Ingenia Ambition 1.5T uses up to 53% less power per patient scan [4].


Philips will also take back the currently-installed Philips equipment and ensure responsible end-of-use management, to avoid waste going to landfill. In addition, Philip will help the Champalimaud Foundation implement hybrid operating room solutions, providing its specialists with a wide range of image-guided minimally-invasive interventional procedures with enhanced precision and patient safety, resulting in shorter hospitalization compared to traditional surgical interventions.

[1] Health Care Without HarmScope 1 direct emissions originate from the hospitals' own operations: emissions from the building and transportation. Scope 2 indirect emissions are generated by the production and distribution of energy that is consumed by the hospital. Scope 3 are indirect CO2 emissions caused by the production and transportation of goods and services needed by hospitals such as medicines, food, equipment, clothing and waste treatment.
[2] https://www.bmj.com/content/366/bmj.l5560
[3] When compared to an equivalent CT model of one of the industry leaders
[4] Applicable to Ambition S. Philips SmartSpeed power consumption versus Philips SENSE based scanning. Based on COCIR and in-house simulated environment. Results can vary based on site conditions.


For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

Afonso Vaz Pinto
Champalimaud Foundation
E-mail: avazpinto@jlma.pt
Tel: +34 969 658 256

Raul Araújo
Champalimaud Foundation
Email: raraujo@jma.pt
Tel: +34 927 414 665

About Royal Philips

Royal Philips.

About Champalimaud Foundation:

The Champalimaud Foundationwas created in 2004 by the last will and testament of the Portuguese entrepreneur António Champalimaud. It is one of the largest European foundations dedicated to scientific research in the field of Medicine. The Champalimaud Foundation essentially supports research in neurosciences, cancer and vision.
The mission of the Champalimaud Clinical Center (CCC) is to actively develop advanced research and technological innovation programs, alongside the interdisciplinary delivery of clinical care in the prevention, early diagnosis and treatment of cancer. Its clinical activity is patient-centered, through the personalization of care and promotion of quality of life, providing excellence in care, based on multidisciplinary teams, and providing patients with the opportunity to participate in innovative diagnostic and treatment programs.

Attachments

  • Philips MR - Ingenia Ambition 1.5T (https://ml-eu.globenewswire.com/Resource/Download/8ae49df6-ecd4-4d33-a6a7-e7557e4e571c)
  • Philips Spectral CT 7500 (https://ml-eu.globenewswire.com/Resource/Download/21f60241-fa96-46aa-8bc8-a6ec3636d5bd)
  • Philips Champalimaud partnership signing (https://ml-eu.globenewswire.com/Resource/Download/ee8cd710-c027-466a-bdd9-4e718fda0c70)

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.